NEW YORK--(BUSINESS WIRE)--Today, Celmatix, a next-generation women’s health company, announced that Lori Batta, a seasoned healthcare executive with more than 25 years of experience, has been promoted to the role of Chief Commercial Officer (CCO). This announcement comes on the heels of the recent news that the company’s Fertilome® genetic test has received full regulatory approval by the New York State (NYS) Department of Health (DOH) Clinical Laboratory Evaluation Program (CLEP), becoming the first multigene panel test for reproductive conditions to receive this approval.
In her newly expanded role, Batta will be responsible for the successful execution of the company's commercial strategy both organically and through strategic alliances for both the Fertilome test and the Polaris® analytics platform, as well as helping to evaluate opportunities for international expansion. She will oversee the sales and customer support functions, as well as lead strategic alliances.
Batta previously served as Senior Vice President of Sales for Celmatix. Prior to joining the company, she was Senior Vice President, Business Development and Strategic Alliances, at Good Start Genetics, Inc. (GSG), a pioneering genetic testing company, where she led the company’s global business development strategy. During her time at GSG, Batta was responsible for the launch of the first next-generation sequencing carrier screen and drove more than $100M in revenue in its first three years in the market. She has also held senior roles at MDR Specialty Pharmacy, EMD Serono, and Novartis.
“In Lori’s first 12 months with the company, she has already played a significant role in guiding our company through the initial commercial launch of our Fertilome test, laying a solid foundation for future growth,” said Piraye Yurttas Beim, PhD, Founder and CEO of Celmatix. “Now that we have full regulatory approval for the test, we will be ramping our commercial efforts in 2018. Lori’s unique expertise and experience make her an ideal leader for these important initiatives. I look forward to partnering with her to achieve our mission of bringing the personalized medicine tools that are powering better outcomes in oncology to women’s reproductive health.”
“When I joined Celmatix, I knew the company was at an important inflection point,” said Lori Batta, CCO, Celmatix. “In my new role, I am excited to lead the commercial charge for this incredible team that is on the forefront of revolutionizing women's health and continuing our progress towards commercial scale and profitability.”
To learn more about career opportunities with Celmatix, please visit https://celmatix.com/careers.
About Celmatix Inc.
Celmatix is a next-generation women’s health company transforming reproductive health care through genomics and big data. Founded in 2009 and based in New York City, Celmatix is disrupting how women approach their lifelong fertility journey by empowering them and their physicians with more personalized information. The company’s research-driven products include the Fertilome® test, the world’s first multigene panel test that reveals what a woman’s DNA says about her reproductive health, and Polaris®, a real-time predictive analytics platform in use at leading fertility clinics across the U.S., which helps physicians optimize patient outcomes and improve the patient experience.
